CO2024001256A2 - Compuesto inductor de la degradación de plk1 novedoso - Google Patents
Compuesto inductor de la degradación de plk1 novedosoInfo
- Publication number
- CO2024001256A2 CO2024001256A2 CONC2024/0001256A CO2024001256A CO2024001256A2 CO 2024001256 A2 CO2024001256 A2 CO 2024001256A2 CO 2024001256 A CO2024001256 A CO 2024001256A CO 2024001256 A2 CO2024001256 A2 CO 2024001256A2
- Authority
- CO
- Colombia
- Prior art keywords
- plk1
- degradation
- novel
- inducing compound
- present disclosure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000015556 catabolic process Effects 0.000 title abstract 3
- 238000006731 degradation reaction Methods 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 101150073897 plk1 gene Proteins 0.000 title 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 abstract 3
- 108010056274 polo-like kinase 1 Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación se refiere a un compuesto inductor de la degradación de PLK1 novedoso, a un método para preparar el mismo y al uso del mismo. Los compuestos de la presente divulgación exhiben un efecto de inducción de la degradación de PLK1. Por lo tanto, los compuestos de la presente divulgación pueden utilizarse eficazmente para prevenir o tratar enfermedades relacionadas con PLK1.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210105358 | 2021-08-10 | ||
| KR20210106488 | 2021-08-12 | ||
| KR20210117389 | 2021-09-03 | ||
| KR20210126757 | 2021-09-24 | ||
| KR20220008456 | 2022-01-20 | ||
| KR20220020996 | 2022-02-17 | ||
| KR20220054880 | 2022-05-03 | ||
| KR20220075838 | 2022-06-21 | ||
| PCT/KR2022/011961 WO2023018236A1 (en) | 2021-08-10 | 2022-08-10 | Novel plk1 degradation inducing compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001256A2 true CO2024001256A2 (es) | 2024-03-18 |
Family
ID=85200656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001256A CO2024001256A2 (es) | 2021-08-10 | 2024-02-06 | Compuesto inductor de la degradación de plk1 novedoso |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11912710B2 (es) |
| EP (4) | EP4384521A1 (es) |
| JP (2) | JP2024530195A (es) |
| KR (5) | KR102604802B1 (es) |
| CN (2) | CN116261458B (es) |
| AU (1) | AU2022327025A1 (es) |
| CA (1) | CA3228601A1 (es) |
| CL (1) | CL2024000373A1 (es) |
| CO (1) | CO2024001256A2 (es) |
| CR (1) | CR20240120A (es) |
| EC (1) | ECSP24010109A (es) |
| IL (1) | IL310678A (es) |
| MX (1) | MX2024001774A (es) |
| PE (1) | PE20240894A1 (es) |
| WO (5) | WO2023017446A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102313752B1 (ko) * | 2020-03-27 | 2021-10-19 | (주) 업테라 | Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물 |
| WO2024162828A1 (en) * | 2023-02-02 | 2024-08-08 | Uppthera, Inc. | Novel plk1 degradation inducing compound |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2381212T3 (es) * | 2006-04-12 | 2012-05-24 | Vertex Pharmaceuticals Incorporated | 4,5-Dihidro-[1,2,4]triazolo[4,3-F]pteridinas como inhibidores de la proteincinasa PLK1 para el tratamiento de trastornos proliferativos |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| AU2016349781A1 (en) | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| CN106543185B (zh) | 2016-11-10 | 2017-12-15 | 吉林大学 | 一种靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| CN106977584B (zh) | 2017-04-19 | 2019-12-06 | 吉林大学 | 靶向泛素化降解plk1和brd4蛋白的化合物及其应用 |
| US20200038513A1 (en) | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| CN111018857B (zh) * | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | 靶向蛋白酶降解平台(ted) |
| CN109879877B (zh) * | 2019-03-04 | 2021-08-10 | 吉林大学 | 一种可降解plk1和brd4蛋白的化合物及其应用 |
| EP4034132A4 (en) | 2019-09-27 | 2023-10-11 | Dana-Farber Cancer Institute, Inc. | ERK5 DEGRADER AS THERAPEUTIC FOR CANCER AND INFLAMMATORY DISEASES |
-
2022
- 2022-08-10 IL IL310678A patent/IL310678A/en unknown
- 2022-08-10 EP EP22856233.6A patent/EP4384521A1/en active Pending
- 2022-08-10 JP JP2024507884A patent/JP2024530195A/ja active Pending
- 2022-08-10 CA CA3228601A patent/CA3228601A1/en active Pending
- 2022-08-10 JP JP2024507883A patent/JP2024530495A/ja active Pending
- 2022-08-10 EP EP22808931.4A patent/EP4157850A1/en active Pending
- 2022-08-10 WO PCT/IB2022/057475 patent/WO2023017446A1/en active Application Filing
- 2022-08-10 EP EP22855629.6A patent/EP4384520A1/en active Pending
- 2022-08-10 CN CN202280006544.1A patent/CN116261458B/zh active Active
- 2022-08-10 KR KR1020227036596A patent/KR102604802B1/ko active IP Right Grant
- 2022-08-10 WO PCT/KR2022/011963 patent/WO2023018238A1/en unknown
- 2022-08-10 WO PCT/KR2022/011962 patent/WO2023018237A1/en active Application Filing
- 2022-08-10 WO PCT/IB2022/057471 patent/WO2023017442A1/en active Application Filing
- 2022-08-10 EP EP22808930.6A patent/EP4157849A1/en active Pending
- 2022-08-10 CN CN202280006505.1A patent/CN116322700B/zh active Active
- 2022-08-10 CR CR20240120A patent/CR20240120A/es unknown
- 2022-08-10 KR KR1020247013823A patent/KR20240060721A/ko active Application Filing
- 2022-08-10 WO PCT/KR2022/011961 patent/WO2023018236A1/en active Application Filing
- 2022-08-10 US US18/019,047 patent/US11912710B2/en active Active
- 2022-08-10 KR KR1020227046443A patent/KR102662205B1/ko active IP Right Grant
- 2022-08-10 US US18/019,034 patent/US11939334B2/en active Active
- 2022-08-10 PE PE2024000208A patent/PE20240894A1/es unknown
- 2022-08-10 KR KR1020227036557A patent/KR102604801B1/ko active IP Right Grant
- 2022-08-10 MX MX2024001774A patent/MX2024001774A/es unknown
- 2022-08-10 AU AU2022327025A patent/AU2022327025A1/en active Pending
- 2022-08-10 KR KR1020227042318A patent/KR102604803B1/ko active IP Right Grant
-
2024
- 2024-02-06 CO CONC2024/0001256A patent/CO2024001256A2/es unknown
- 2024-02-06 CL CL2024000373A patent/CL2024000373A1/es unknown
- 2024-02-07 EC ECSENADI202410109A patent/ECSP24010109A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001256A2 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| CL2022003434A1 (es) | Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378) | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| CO2020012824A2 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| CO2021016594A2 (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| CL2020000408A1 (es) | Formas sólidas cristalinas de un inhibidor de bet. (solicitud divisional 201803702). | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| CO2019005534A2 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| DOP2018000148A (es) | Compuestos de isoindol | |
| CL2020001147A1 (es) | Compuestos antibacterianos | |
| AR117835A1 (es) | Complejo diastereoisomérico enriquecido de gadolinio y de un ligando quelante a base de pcta, y proceso de preparación y purificación del mismo | |
| CL2020002139A1 (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado. | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| CL2021000421A1 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende. | |
| CL2024000250A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras |